#1 Clinical Trials Search in Europe

Nadroparin Calcium

Nadroparin Calcium, a low molecular weight heparin, has been the subject of several clinical trials investigating its effectiveness and safety in treating various medical conditions. These trials have focused on its use in preventing and treating thrombosis, managing portal vein thrombosis in cirrhotic patients, and exploring its potential benefits in cancer patients undergoing chemotherapy. This article summarizes the key findings from these clinical trials, providing insights into the diverse applications of Nadroparin Calcium in modern medicine.

Table of Contents

What is Nadroparin Calcium?

Nadroparin Calcium is a type of medication known as a low molecular weight heparin (LMWH). It is an anticoagulant, which means it helps prevent blood clots from forming or growing larger. This medication is also known by other names, including Fraxiparin and Fraxiparine[1]. Understanding what Nadroparin Calcium is and how it works can help patients better manage their treatment and expectations.

Medical Conditions Treated

Nadroparin Calcium is used to treat and prevent various medical conditions related to blood clotting. Some of the conditions it’s commonly used for include:

  • Thrombophilia in pregnancy: This is a condition where pregnant women have an increased risk of developing blood clots[1].
  • Portal vein thrombosis (PVT): A blood clot in the portal vein, which carries blood from the intestines to the liver. This condition often occurs in patients with liver cirrhosis[2].
  • Venous thromboembolism (VTE): This includes deep vein thrombosis (DVT) and pulmonary embolism (PE)[3].
  • Prevention of blood clots in cancer patients: Especially those undergoing chemotherapy[4].
  • Isolated distal deep-vein thrombosis (IDDVT): Blood clots in the calf veins[5].

How Nadroparin Calcium Works

Nadroparin Calcium works by interfering with the blood’s clotting process. It specifically targets a clotting factor called Factor Xa, which plays a crucial role in blood coagulation. By inhibiting Factor Xa, Nadroparin Calcium helps prevent new clots from forming and existing clots from growing larger[1]. This mechanism of action makes it effective in treating and preventing various thrombotic (clotting) conditions.

Administration and Dosage

Nadroparin Calcium is typically administered as a subcutaneous injection, which means it’s injected just under the skin. The dosage and frequency of administration can vary depending on the specific condition being treated and the patient’s individual characteristics. Some common dosing regimens include:

  • Daily injections: For example, 0.3 mL daily during pregnancy and six weeks postpartum for thrombophilia[1].
  • Twice daily injections: In some cases, such as for portal vein thrombosis, it may be given every 12 hours[2].
  • Weight-based dosing: Some protocols adjust the dose based on the patient’s weight, such as 85 IU/kg every 12 hours[6].

It’s crucial for patients to follow their healthcare provider’s instructions carefully regarding dosage and administration.

Effectiveness and Benefits

Research has shown that Nadroparin Calcium can be effective in various clinical scenarios:

  • Pregnancy complications: It may help reduce the risk of pregnancy-associated thrombosis, miscarriage, preeclampsia, and intrauterine growth retardation in women with thrombophilia[1].
  • Portal vein thrombosis: Studies have shown promising results in achieving recanalization (reopening) of blocked portal veins[2].
  • Cancer-associated thrombosis: It may help prevent blood clots in cancer patients undergoing chemotherapy[4].
  • Isolated distal deep-vein thrombosis: Nadroparin may help prevent the extension of calf vein clots to more dangerous proximal (upper leg) veins[5].

Potential Side Effects and Risks

While Nadroparin Calcium can be effective, it’s important for patients to be aware of potential side effects and risks:

  • Bleeding: As an anticoagulant, the main risk associated with Nadroparin is an increased risk of bleeding. This can range from minor bleeding (such as nosebleeds or bruising easily) to more serious bleeding events[5].
  • Injection site reactions: Some patients may experience irritation, pain, or bruising at the injection site[7].
  • Thrombocytopenia: In rare cases, Nadroparin can cause a decrease in platelet count[1].

Patients should report any unusual bleeding or other concerning symptoms to their healthcare provider immediately.

Ongoing Research

Nadroparin Calcium continues to be the subject of ongoing research to further understand its benefits and optimal use in various conditions:

  • Cirrhosis and portal vein thrombosis: Studies are investigating the use of Nadroparin in patients with liver cirrhosis who develop portal vein thrombosis[8].
  • Cancer treatment: Research is exploring whether Nadroparin can improve survival and slow disease progression in patients with advanced cancers of the lung, pancreas, or prostate[9].
  • Post-endoscopic therapy: Studies are examining the safety and efficacy of Nadroparin after endoscopic treatments for variceal bleeding in cirrhosis patients[7].

These ongoing studies may provide new insights into the potential uses and benefits of Nadroparin Calcium in the future.

Aspect Details
Primary Uses Prevention and treatment of thrombosis, management of portal vein thrombosis, prevention of venous thromboembolism in cancer patients
Administration Subcutaneous injection, typically once or twice daily
Duration of Treatment Varies by condition; ranges from weeks to several months
Key Outcomes Measured Recanalization rates, bleeding events, survival rates, thrombotic events
Patient Populations Pregnant women with thrombophilia, cirrhotic patients with portal vein thrombosis, cancer patients undergoing chemotherapy
Safety Considerations Risk of bleeding, careful monitoring of INR levels, potential for thrombocytopenia
Comparative Studies Compared with placebo, warfarin, and other interventions like TIPS

FAQ

  • What is Nadroparin Calcium? Nadroparin Calcium is a low molecular weight heparin used as an anticoagulant. It helps prevent blood clots and is being studied for various medical conditions, including thrombosis, portal vein thrombosis, and cancer-related complications.
  • How is Nadroparin Calcium administered? Nadroparin Calcium is typically administered through subcutaneous injection. The dosage and frequency can vary depending on the condition being treated and the specific trial protocol. In some studies, it's given once or twice daily.
  • What conditions are being studied using Nadroparin Calcium? Clinical trials are exploring the use of Nadroparin Calcium in various conditions, including pregnancy-associated thrombosis, portal vein thrombosis in cirrhotic patients, prevention of venous thromboembolism in cancer patients, and management of deep vein thrombosis.
  • Are there any potential side effects of Nadroparin Calcium? As with any anticoagulant, the main concern with Nadroparin Calcium is the risk of bleeding. Clinical trials are carefully monitoring for major and minor bleeding events. Other potential side effects may include injection site reactions or thrombocytopenia (low platelet count).
  • How long does treatment with Nadroparin Calcium typically last? The duration of treatment varies depending on the condition and study protocol. In the trials mentioned, treatment durations ranged from a few weeks to several months. For example, in pregnancy-related studies, it was used throughout pregnancy and for six weeks postpartum, while in cancer-related studies, it was used for up to 4 months.

Ongoing Clinical Trials on Nadroparin Calcium

  • Evaluation of enoxaparin, dalteparin, nadroparin, tinzaparin and human albumin in adults admitted to intensive care unit with acute critical illness

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark Finland Iceland The Netherlands Sweden

  • Study on the Effects of Nadroparin Calcium in Patients with Subarachnoid Hemorrhage

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Venous Thromboembolism Prevention with Enoxaparin Sodium and Drug Combination for Patients Undergoing Total Hip or Knee Replacement

    Recruiting

    1 1 1 1
    Investigated drugs:
    The Netherlands

  • Study Comparing Rivaroxaban and Drug Combination for Preventing Blood Clots in Patients with Lower Limb Injuries Requiring Immobilization

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Heparin and Nadroparin Calcium for Patients Undergoing ECMO Treatment to Reduce Bleeding Risks

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    The Netherlands

Glossary

  • Thrombophilia: A condition where the blood has an increased tendency to form clots, which can lead to various complications.
  • Portal Vein Thrombosis (PVT): A blood clot that forms in the portal vein, which carries blood from the intestines to the liver.
  • Cirrhosis: A late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions.
  • Venous Thromboembolism (VTE): A condition where a blood clot forms in a vein, typically in the leg (deep vein thrombosis) or lungs (pulmonary embolism).
  • Recanalization: The restoration of blood flow through a previously blocked blood vessel.
  • International Normalized Ratio (INR): A standardized measurement of blood clotting time used to determine the effects of oral anticoagulants.
  • Transjugular Intrahepatic Portosystemic Shunt (TIPS): A medical procedure to create a new route for blood to flow within the liver, used to treat portal hypertension.
  • Esophageal Variceal Band Ligation: A procedure to treat enlarged veins in the esophagus, often caused by liver cirrhosis, to prevent bleeding.

References

  1. https://clinicaltrials.gov/study/NCT01019655
  2. https://clinicaltrials.gov/study/NCT04173429
  3. https://clinicaltrials.gov/study/NCT01267305
  4. https://clinicaltrials.gov/study/NCT00951574
  5. https://clinicaltrials.gov/study/NCT00421538
  6. https://clinicaltrials.gov/study/NCT02398357
  7. https://clinicaltrials.gov/study/NCT04976543
  8. https://clinicaltrials.gov/study/NCT06319131
  9. https://clinicaltrials.gov/study/NCT00312013